Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
PTHrP treatment of colon cancer cells promotes tumor associated-angiogenesis by the effect of VEGF.
|
30639585 |
2019 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Serum vascular endothelial growth factor (VEGF) concentrations in colon cancer patients of the two groups were evaluated before and after chemotherapy.
|
31127996 |
2019 |
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to evaluate the prognostic value of MVD in stage II and III colon cancer and its relation to tumour-stroma-percentage (TSP) and expression of HIF1A and VEGFA.
|
31420015 |
2019 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Stimulation of colon cancer cells with VEGF-A and placental growth factor (PlGF) activated VEGF receptor-1 (VEGFR-1) and increased proliferation activity in an autocrine EGF/EGF receptor (EGF-R)-dependent manner.
|
31717527 |
2019 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Chemokine receptor 7 targets the vascular endothelial growth factor via the AKT/ERK pathway to regulate angiogenesis in colon cancer.
|
31348616 |
2019 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
A gene signature comprising LAMA1, ITGB1, ITGA2, CXCR4 and VEGFA has negative predictive value in colon cancer.
|
29907957 |
2018 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
The aim was to investigate the predictive value of postoperative VEGF serum concentration in patients undergoing surgery for colon cancer.
|
28683891 |
2018 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
We have used 20 Male wistar rats for the formation of colon cancer model and utilized albumin as carrier molecule for the delivery of siRNA against vascular endothelial growth factor receptor 2 (VEGF R2).
|
29709588 |
2018 |
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We examined the effect of genipin on the intracellular level of HIF-1α and extracellular level of VEGF using the colon cancer cell line HCT116.
|
29630948 |
2018 |
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
miR‑1 inhibits the progression of colon cancer by regulating the expression of vascular endothelial growth factor.
|
29845255 |
2018 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
The rationale for this therapeutic approach is based on the fact that antiangiogenic drugs can make tumors hypoxic, and thus more sensitive to PIM inhibitors.<b>Experimental Design:</b> Xenograft and orthotopic models of prostate and colon cancer were used to assess the effect of PIM activation on the efficacy of VEGF-targeting agents.
|
29084916 |
2018 |
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the efficacy of bevacizumab-based anti-angiogenesis in combination with PDT as well as the resulting VEGF levels and microvessel density (MVD) in a mouse model of human colon cancer.
|
29894822 |
2018 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
ALA PDT used in sublethal doses decreases release of VEGF in more aggressively growing SW620 colon cancer cell line in hypoxia-like conditions.
|
29079348 |
2018 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
We evaluated the influence of 28 single-nucleotide polymorphisms in 12 genes in the VEGF pathway on the prognosis of 347 patients with stage II-III colon cancer.
|
29282362 |
2018 |
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These factors could allow neoplastic tissues to survive and withstand the stress induced by hypoxia and/or disruption of the ECM, including vascular endothelial growth factor and matrix metalloproteinases that were found to be highly elevated in tumor tissues of colon cancer patients.
|
28245762 |
2017 |
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that colon cancer cells express high levels of VEGF, total HER2 and phosphorylated HER2, and simvastatin apparently decreased their expression in HER2-overexpressing colon cancer cells.
|
27887848 |
2017 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Bevacizumab, an inhibitor of vascular endothelial growth factor (VEGF)-A, is currently used to treat patients with ovarian or colon cancer.
|
28966326 |
2017 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Biopsies were collected from 86 patients with advanced colon cancer and sections were stained by immunohistochemistry for VEGF.
|
28245709 |
2017 |
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Elevated TATA-binding protein expression drives vascular endothelial growth factor expression in colon cancer.
|
28415573 |
2017 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Taken together, our study provides evidences showing that miR-299-3p functions as a suppressor in colon cancer by targeting VEGFA, suggesting that miR-299-3p might serve as a novel target for colon cancer therapy.
|
28738498 |
2017 |
Malignant tumor of colon
|
0.600 |
Biomarker
|
disease |
BEFREE |
Smad4 Inhibits VEGF-A and VEGF-C Expressions via Enhancing Smad3 Phosphorylation in Colon Cancer.
|
28445620 |
2017 |
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Collectively, our results indicate that SARI is a potential target for therapy by inhibiting angiogenesis through the reduction of VEGF expression and is a prognostic indicator for patients with colon cancer.
|
27353863 |
2016 |
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer.
|
25371074 |
2015 |
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis.
|
26209639 |
2015 |
Malignant tumor of colon
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This study showed that Lcn2-engineered MSCs (MSC-Lcn2) not only inhibited liver metastasis of colon cancer but also downregulated the expression of vascular endothelial growth factor (VEGF) in the liver.
|
25740061 |
2015 |